UK investigates weight-loss jab risks after many hospitalised with pancreatitis

The UK's MHRA and Genomics England are launching a study to investigate genetic predispositions to acute pancreatitis in users of GLP-1 receptor agonists like Ozempic, Mounjaro, and Wegovy. This initiative follows significant adverse event reports, including 181 cases of pancreatitis linked to Mounjaro and 113 to Ozempic/Wegovy, some with fatal outcomes. The research, utilizing the Yellow Card Biobank to collect patient genetic data, aims to identify risk factors for personalized medicine, potentially influencing prescribing practices and impacting the market outlook for major pharmaceutical companies in the rapidly expanding GLP-1 sector.

Analysis

The UK's Medicines and Healthcare products Regulatory Agency (MHRA), in partnership with Genomics England, is launching a formal investigation into a potential genetic link for acute pancreatitis in patients using GLP-1 receptor agonists. This regulatory action is a direct response to a significant number of adverse event reports, specifically 181 cases of pancreatitis including five fatalities linked to Eli Lilly's Mounjaro, and 113 cases with one fatality associated with Novo-Nordisk's Wegovy and Ozempic. The study, utilizing the Yellow Card Biobank, signals a proactive shift towards personalized medicine by aiming to identify genetic markers that could predict and prevent severe side effects. For the manufacturers, Eli Lilly (LLY) and Novo-Nordisk (NVO), this development introduces a material headline and regulatory risk to their blockbuster drug franchises. While pancreatitis is a known rare side effect, this high-profile investigation could lead to stricter prescribing guidelines, potential requirements for genetic screening, and negatively impact public and physician perception, thereby posing a threat to the current growth trajectory of the GLP-1 market.

Key Decisions for Investors

• Investors with exposure to Eli Lilly (LLY) and Novo-Nordisk (NVO) should treat this investigation as a significant near-term risk factor, closely monitoring for any findings that could alter prescribing guidelines or market access.
• Re-evaluate risk models for both companies to account for potential litigation costs and reputational damage stemming from the reported fatalities and adverse events.
• Consider the potential for market share differentiation between LLY and NVO if the study reveals a disparate genetic risk profile associated with their respective GLP-1 products.
• While a headwind now, a successful outcome from the study identifying clear genetic markers could eventually de-risk the GLP-1 class, potentially creating a more stable, albeit more restricted, long-term market.